Elsevier

Journal of Infection

Volume 69, Supplement 1, November 2014, Pages S19-S22
Journal of Infection

Neonatal candidiasis: Diagnosis, prevention, and treatment

https://doi.org/10.1016/j.jinf.2014.07.012Get rights and content

Summary

Infection with Candida species is associated with significant morbidity and mortality in infants.

The incidence of Candida infection varies widely across centers, likely due to differences in practice related to modifiable risk factors such as exposure to empiric antibiotics and length of parenteral nutrition. Early diagnosis of Candida and prompt treatment with appropriate antifungal agents, such as fluconazole, amphotericin B deoxycholate, and micafungin, are critical for improved outcomes. This paper reviews the current literature relating to the prevention, diagnosis, and treatment of Candida infections in the neonatal intensive care unit.

Introduction

Infection with Candida species is associated with significant morbidity and mortality in infants. Extremely low birth weight (ELBW; <1000 g) infants carry the highest burden of disease. The incidence of candidiasis in ELBW infants is approximately 10%, although it varies as much as 20-fold between centers.1, 2 Neonatal candidiasis is associated with 20% mortality, and 50% of survivors have severe neurodevelopmental impairment.3 End-organ damage in the central nervous system, heart, and genitourinary tract is also common.4 Few clinical signs or laboratory assays have been validated for candidiasis in infants, thus prevention of infection is critical. When infection occurs, treatment with appropriate antimicrobial agents must be prompt.

Section snippets

Diagnosis

The blood culture is the gold standard for detection of candidiasis, although its sensitivity is poor.5 Even with multiple organs infected with candidiasis, the sensitivity of blood culture to detect infection in adults is only 50%.6 The small blood volume used for culture in infants makes isolation of Candida species in blood (candidemia) even more difficult. Because four or more vital organs are typically involved prior to documentation of candidemia, a positive blood culture for Candida

Prevention

Previous investigators have identified risk factors associated with Candida infection in infants.3, 13 Some of these risk factors, such as gestational age and birth weight, cannot be altered. However, multiple modifiable risk factors have been identified; foremost among these is prolonged exposure to empiric antibiotics (greater than 48 h despite negative blood cultures) and exposure to third-generation cephalosporins and other broadly-acting antibiotics such as carbapenems and

Treatment

Prompt treatment is critical to improving outcomes for infants with candidiasis. If clinicians await a positive blood culture prior to starting therapy, treatment can be delayed as much as 72 h. In ELBW infants, empirical antifungal therapy (receipt of therapy on the day of or the day before the first positive blood culture for Candida) is associated with increased survival without neurodevelopmental impairment.17 Thus, empirical antifungal therapy should be considered in high-risk infants once

Summary and recommendations

Candidiasis in the intensive care nursery results in substantial morbidity and mortality. Prevention of infection is possible via modification of risk factors. Early diagnosis is critical, and treatment should be initiated promptly with appropriate antifungal agents. Empirical antifungal therapy should be considered when Candida is suspected in ELBW infants. When infection with Candida is diagnosed, the following steps should be followed:

  • 1)

    Central venous and arterial catheters should be removed.

Conflicts of interest

Dr. Benjamin receives support from the United States Government for his work in pediatric and neonatal clinical pharmacology (1R01HD057956-05, 1K24HD058735-05, UL1TR001117, and NICHD contract HHSN275201000003I) and the nonprofit organization Thrasher Research Fund for his work in neonatal candidiasis (www.thrasherresearch.org); he also receives research support from industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). Dr. Greenberg has no potential

References (35)

  • F. Lamoth et al.

    beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)

    Clin Infect Dis

    (2012)
  • L. Senn et al.

    1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia

    Clin Infect Dis

    (2008)
  • R. Wahyuningsih et al.

    Simple and rapid detection of Candida albicans DNA in serum by PCR for diagnosis of invasive candidiasis

    J Clin Microbiol

    (2000)
  • G. Morace et al.

    PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies

    J Clin Microbiol

    (1999)
  • L. Saiman et al.

    Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group

    Pediatr Infect Dis J

    (2000)
  • D. Kaufman et al.

    Fluconazole prophylaxis against fungal colonization and infection in preterm infants

    N Engl J Med

    (2001)
  • P. Manzoni et al.

    A multicenter, randomized trial of prophylactic fluconazole in preterm neonates

    N Engl J Med

    (2007)
  • Cited by (47)

    • Infections of the Skin

      2023, Avery's Diseases of the Newborn
    • Infection prevention for extremely low birth weight infants in the NICU

      2022, Seminars in Fetal and Neonatal Medicine
      Citation Excerpt :

      Minimizing risk factors for fungal sepsis is an important way to minimize the risk of disease. Modifiable risk factors include: prolonged exposure to empiric antibiotics, exposure to 3rd generation cephalosporins and other broad-spectrum antibiotics, and use of foreign bodies (such as endotracheal tubes, central venous or arterial catheters and other hardware) [91,92]. Other risk factors for invasive fungal disease include positive pressure ventilation and intubation, gastrointestinal pathology, previous blood stream infection, parenteral nutrition and intravenous lipids [92].

    • Distinct innate immune responses between sublethal and lethal models of disseminated candidiasis in newborn BALB/c mice

      2021, Microbial Pathogenesis
      Citation Excerpt :

      Neonatal invasive candidiasis occurs within the first four weeks of life, characterized by fungal invasion of the skin, mucous membranes (eyes, genitourinary tract) and brain. In newborns, the central nervous system is the principal site of dissemination causing meningitis [2,5,6], which is associated with a poor prognosis since meningitis is present in up to 60% of fatal cases, while patients who survive have a high incidence of severe neurological sequelae, including: hydrocephalus, psychomotor delay and intellectual disability [6,7]. The neonatal immune system has been considered an important risk factor for candidiasis, attributed to functional differences in both neonatal innate [8] and adaptive immunity [9] between neonates and adults.

    • The Impact of Rapid Species Identification on Management of Bloodstream Infections: What's in a Name?

      2020, Mayo Clinic Proceedings
      Citation Excerpt :

      Preterm infants are particularly susceptible to invasive Candida infections, including meningitis, and the isolation of fungus from the bloodstream necessitates investigation of the central nervous system. Neonatal candidiasis is associated with 20% mortality, and 50% of survivors have severe neurodevelopmental impairment.60,61 Amphotericin B deoxycholate is well-tolerated in infants; lipid formulations can also be used, but are not preferred.62

    View all citing articles on Scopus
    View full text